Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Files An 8-K Other Events

ME Staff 8-k
-
0

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Files An 8-K Other Events
Item 8.01 Other Events.

On September 20, 2017, Eagle Pharmaceuticals, Inc., or the Company, issued a press release announcing that the Company has licensed to SymBio Pharmaceuticals Limited rights under the Company’s intellectual property to develop, market and sell the Company’s bendamustine hydrochloride ready-to-dilute and rapid infusion injection products in Japan.

A copy of the press release referenced above is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

ExhibitNo.

Description

99.1

Press Release dated September 20, 2017


EAGLE PHARMACEUTICALS, INC. Exhibit
EX-99.1 2 a17-22282_1ex99d1.htm EX-99.1 Exhibit 99.1     For Immediate Release   Eagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited   – Begins Process to Maximize Value of Eagle’s Product Portfolio Worldwide —   – $12.5 Million Upfront Payment Plus Future Potential Milestones and Royalty Payments –   WOODCLIFF LAKE,…
To view the full exhibit click here

About Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX)

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes EP-1101 (argatroban); Ryanodex (dantrolene sodium); docetaxel injection, non-alcohol formulation (Non-Alcohol Docetaxel Injection); diclofenac-misoprostol; EP-3101 (Bendamustine Hydrochloride Injection, ready-to-dilute (RTD) concentrate solution), and EP-3102 (rapidly infused bendamustine RTD) (EP-3102 Bendeka). It has over four product candidates in advanced stages of development, and/or under review for approval by the United States Food and Drug Administration (FDA), which include EP-6101 Kangio ready-to-use (RTU) bivalirudin; EP-4104 (dantrolene sodium) (EP-4104) for exertional heat stroke (EHS), and EP-5101 (pemetrexed) (EP-5101). Its near-term product candidate, Kangio is a liquid intravenous form of Angiomax for percutaneous transluminal angioplasty.